Real-World Treatment Patterns and Physician Perspectives in Relapsed/Refractory Multiple Myeloma: Results From a Nationwide Italian GIMEMA Survey [0.03%]
意大利GIMEMA全国调查的复发/难治多发性骨髓瘤的真实世界治疗模式和医生观点
Francesca Fazio,Alfonso Piciocchi,Paolo de Fabritiis et al.
Francesca Fazio et al.
Background: The management of relapsed/refractory multiple myeloma (RRMM) remains complex due to early exposure to multiple drug classes since the first treatment line. ...
Efficacy and Safety of Daratumumab-Based Regimens in Multiple Myeloma: A Systematic Review and Meta-Analysis of Phase III Randomized Controlled Trials [0.03%]
达雷妥尤单抗为基础的方案在多发性骨髓瘤中疗效和安全性的系统评价和Meta分析
Abdul Moiz Khan,Hafsa Ajmal,Muddassir Khalid et al.
Abdul Moiz Khan et al.
Introduction: Multiple myeloma is a malignant plasma cell disorder predominantly affecting older adults and poses a significant health burden due to its incurable nature, high relapse rate, and associated immune dysfuncti...
Candida oesophagitis as an Initial Manifestation of VEXAS Syndrome: Expanding Evidence for an Acquired Immunodeficiency Phenotype [0.03%]
念珠菌性食管炎作为VEXAS综合征初始表现的病例报道:一种获得性免疫缺陷表型的证据补充
Demi Rianne Vintges,Marina Weerheim,Faiz Karim
Demi Rianne Vintges
Patient Understanding of Multiple Myeloma and Communication Experiences (PUMMaCE): Results From a UK Survey [0.03%]
英国一项关于多发性骨髓瘤患者理解和沟通经历的调查结果(PUMMaCE)
Valerie Jenkins,Rachel Hunter,Ruth Habibi et al.
Valerie Jenkins et al.
Introduction: Multiple myeloma (MM) is a complex haematological cancer. The terminology used can make discussions more challenging. We designed an online patient survey to explore this area. ...
Primary CNS Anaplastic Large Cell Lymphoma DUPS22 Rearranged with Gain of ALK: A Case Report and Review of the Literature [0.03%]
ALKL重排伴DUSP22获得的原发CNS间变性大细胞淋巴瘤一例报告及文献复习
Sindu Iska,María Herrán,Zackary Anderson et al.
Sindu Iska et al.
ALK-negative anaplastic large cell lymphoma (ALCL) is a rare primary central nervous system lymphoma (PCNSL). Although DUSP22 rearrangement is considered favorable in systemic ALK-negative ALCL, survival remains poor in PCNSL. We report a c...
Glofitamab in Heavily Pretreated Mantle Cell Lymphoma Patients: A Multicenter Real-World Case Series [0.03%]
全球多中心真实世界系列案例:既往接受过多种治疗的套细胞淋巴瘤患者使用戈利妥单抗疗效分析
Natalia Rotter,Markus Raderer,Agnes List et al.
Natalia Rotter et al.
Background: Relapsed or refractory mantle cell lymphoma (r/r MCL) remains difficult to treat despite therapeutic advances. Methods: Thi...
A Delphi Consensus on Optimising the Care Pathway for Adult Patients With Acute Myeloid Leukaemia (AML): Strategies to Enhance Transplant Accessibility and Feasibility in the United Kingdom [0.03%]
关于优化成人急性髓系白血病患者护理路径的德菲共识:在英国提高移植可及性和可行性的策略
Priyanka Mehta,Francesca A M Kinsella,Thomas P Coats et al.
Priyanka Mehta et al.
Background: Allogeneic haematopoietic stem cell transplant (allo-HSCT) is a curative option for a large proportion of acute myeloid leukaemia (AML) patients, but availability remains challenging and transplantation is und...
Spontaneous Acute Left-Sided Abdominal Pain in a Patient With AL Amyloidosis [0.03%]
淀粉样变性病患者的急性左上腹痛病例报告
Shahzil Abdur Rehman Malik,Utkarsh Goel,Jason Valent et al.
Shahzil Abdur Rehman Malik et al.
Pragmatic Clinical Trial of Fostamatinib as Second-Line Therapy in Adult Patients With Immune Thrombocytopenia and Insufficient Response to Prior Therapy: The Fostamatinib FORTE Trial [0.03%]
用于治疗对之前疗法反应不足的成人自身免疫性血小板减少症患者的氟司他丁药物二期临床试验:氟司他丁FORTE试验
Amber Afzal,Robert Kribs,Sumit Sawhney et al.
Amber Afzal et al.
Inhibitory HLA-C/KIR2DL2 Interactions and KIR Allelic Polymorphisms Are Associated With Susceptibility to Philadelphia Chromosome-Negative Myeloproliferative Neoplasms [0.03%]
抑制性HLA-C/KIR2DL2相互作用和KIR等位基因多态性与费城染色体阴性骨髓增生性肿瘤的易感性相关
Velizar Shivarov,Gergana Tsvetkova,Evgueniy Hadjiev et al.
Velizar Shivarov et al.
Background: Immune surveillance is increasingly recognized as a determinant of clonal selection in Philadelphia chromosome-negative myeloproliferative neoplasms (MPN). While HLA-restricted adaptive immune effects have bee...